Does midazolam alter the clinical effects of intravenous ketamine sedation in children? A double-blind, randomized, controlled, emergency department trial


      Study Objective: This study was conducted to investigate the frequency and severity of adverse effects, specifically emergence phenomena, experienced by patients receiving intravenous ketamine with or without midazolam for sedation in a pediatric emergency department. Methods: Patients aged 4.5 months to 16 years receiving ketamine sedation were prospectively enrolled in a double-blind, randomized, controlled study at a university-affiliated children’s hospital–pediatric ED. All patients received ketamine (1 mg/kg) and glycopyrrolate (5 μg/kg) intravenously. Patients were randomly assigned to receive midazolam (0.1 mg/kg) intravenously or no midazolam. Total time of sedation, sedation efficacy, and adverse effects were recorded. Adverse effects were compared between patients receiving ketamine versus those who received ketamine and midazolam. Additional comparisons were made based on age and number of ketamine doses administered. Results: Two hundred sixty-six patients were studied; 129 received ketamine and 137 patients received ketamine and midazolam. Time of sedation and efficacy of sedation were equivalent between groups. Overall, adverse effects with ketamine sedation included respiratory events (12 [4.5%]), vomiting (50 [18.7%]), emergence phenomena in the pediatric ED (71 [26.7%]), and emergence phenomena at home (60 [22.4%]). Significant emergence phenomena in the pediatric ED (ie, nightmares, hallucinations, and severe agitation) occurred in 7.1% of the ketamine group and in 6.2% of the ketamine-midazolam group, a rate difference of 0.8 (95% confidence interval [CI] –5.3 to 7.0). The addition of midazolam led to an increased incidence of oxygen desaturation events (ketamine 1.6% versus ketamine-midazolam 7.3%; rate difference –5.7, 95% CI –10.6 to –0.9) but a decreased incidence of vomiting (ketamine 19.4%, ketamine-midazolam 9.6%, rate difference 9.8, 95% CI 1.4 to 18.2). The incidence of emergence phenomena and significant emergence phenomena was not affected by the addition of midazolam. However, the addition of midazolam was associated with more agitation in the pediatric ED in children 10 years or older (ketamine 5.7% versus ketamine-midazolam 35.7%; rate difference –30.0, 95% CI –10.7 to –49.3). Age breakdown further showed 6.3% (95% CI 0.9 to 11.6) more episodes of oxygen desaturation in the ketamine-midazolam group in children younger than 10 years, and 12.1% (95% CI 1.5 to 22.6) more vomiting episodes in the ketamine group in children younger than 10 years. Conclusion: Ketamine and combined ketamine and midazolam provided equally effective sedation. The addition of midazolam did not alter the incidence of emergence phenomena. Vomiting occurred more frequently in the ketamine only group, whereas oxygen desaturation occurred more frequently in the ketamine-midazolam group. These findings were more pronounced in patients younger than 10 years. Parental and physician satisfaction remained high for all patients receiving intravenous ketamine sedation. [Wathen JE, Roback MG, Mackenzie T, Bothner JP. Does midazolam alter the clinical effects of intravenous ketamine sedation in children? A double-blind, randomized, controlled, emergency department trial. Ann Emerg Med. December 2000;36:579-588.]
      To read this article in full you will need to make a payment
      ACEP Member Login
      ACEP Members, full access to the journal is a member benefit. Use your society credentials to access all journal content and features.

      Purchase one-time access:

      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Corresen G
        • Reeves JG
        • Stanley TH.
        Intravenous Anesthesia and Analgesia.
        in: Lea & Febiger, Philadelphia, PA1988: 99-174
        • Bowdle TA
        • Radant AD
        • Cowley DS.
        Psychedelic effects of ketamine in healthy volunteers.
        Anesthesiology. 1998; 88: 82-88
        • Tweed WA
        • Minuck M
        • Mymin D.
        Circulatory responses to ketamine anesthesia.
        Anesthesiology. 1972; 37: 613-619
        • Fine J
        • Finestone SC.
        Sensory disturbances following ketamine anesthesia: recurrent hallucinations.
        Anesth Analg. 1973; 52: 428-430
        • Coppel DL
        • Bovill JG
        • Dundee JW.
        The taming of ketamine.
        Anaesthesia. 1973; 28: 293-296
        • White PF
        • Way WL
        • Trevor AJ.
        Ketamine—its pharmacology and therapeutic uses.
        Anesthesiology. 1982; 56: 119-136
        • Galloon S.
        Ketamine for dilatation and curettage.
        Can Anaesth Soc J. 1971; 18: 600-613
        • Kothary SP
        • Zsigmond EK.
        A double blind study of the effective antihallucinatory doses of diazepam prior to ketamine anesthesia.
        Clin Pharmacol Ther. 1977; 21: 108-109
        • Toft P
        • Romer U.
        Comparison of midazolam and diazepam to supplement total intravenous anaesthesia with ketamine for endoscopy.
        Can J Anaesth. 1987; 34: 466-469
        • Cartwright PD
        • Pingel SM.
        Midazolam and diazepam in ketamine anaesthesia.
        Anaesthesia. 1984; 39: 439-442
        • Sherwin TS
        • Green SM
        • Khan A
        • et al.
        Does adjunctive midazolam reduce recovery agitation after ketamine sedation for pediatric procedures? A randomized, double-blind, placebo-controlled trial.
        Ann Emerg Med. 2000; 35: 229-238
        • American Society of Anesthesiologists
        New classification of physical status.
        Anesthesiology. 1963; 24: 111
        • Lechner MD
        • Kreuscher H.
        Physikalische kompatibiltat von ketamin und diazepan in infusionslosungen.
        Anesthesist. 1989; 38: 418-420
        • Jay SM
        • Elliott C.
        Behavioral observation scales for measuring children’s distress: the effects of increased methodologic rigor.
        J Consult Clin Psychol. 1984; 52: 1106-1107
        • Elliot CH
        • Jay SM
        • Woody P.
        An observational scale for measuring children’s distress during medical procedures.
        J Pediatr Psychol. 1987; 12: 543-551
        • Macnab AJ
        • Levine M
        • Glick N
        • et al.
        A research tool for measurement from sedation: the Vancouver Sedative Recovery Scale.
        J Pediatr Surg. 1991; 26: 1263-1267
        • Macnab AJ
        • Levine M
        • Glick N
        • et al.
        The Vancouver sedative scale for children: validation and reliability of scoring based on videotaped instruction.
        Can J Anaesth. 1994; 41: 913-918
        • White PF
        • Ham J
        • Way WL.
        Pharmacology of ketamine isomers in surgical patients.
        Anesthesiology. 1980; 52: 231-239
        • Knox JWD
        • Bovill JG
        • Clarke RSJ.
        Clinical studies of induction agents-ketamine.
        Br J Anaesth. 1970; 42: 875-885
        • Krestow M.
        The effect of post-anaesthetic dreaming on patient acceptance of ketamine anaesthesia: a comparison with thiopentone-nitrous oxide anaesthesia.
        Can Anaesth Soc J. 1974; 21: 385-389
        • Little B
        • Chang T
        • Chucot L.
        Study of ketamine as an obstetric anesthesia agent.
        Am J Obstet Gynecol. 1974; 113: 347-360
        • Dundee JW
        • Bovill JG
        • Clarke RSG.
        Problems with ketamine in adults.
        Anaesthesia. 1971; 26: 86-90
        • Pruitt JW
        • Goldwasser MS
        • Sabol SR
        • et al.
        Intramuscular ketamine, midazolam, and glycopyrrolate for pediatric sedation in the emergency department.
        J Oral Maxillofac Surg. 1995; 53: 13-17
        • Parker RI
        • Mahan RA
        • Giugliano D
        • et al.
        Efficacy and safety of intravenous midazolam and ketamine as sedation for therapeutic and diagnostic procedures in children.
        Pediatrics. 1997; 99: 427-431
        • Kennedy RM
        • Porter FL
        • Miller JP
        • et al.
        Comparison of fentanyl/midazolam with ketamine/midazolam for pediatric orthopedic emergencies.
        Pediatrics. 1998; 102: 956-963
        • Marx CM
        • Stein J
        • Tyler MK
        • et al.
        Ketamine-midazolam versus meperidine-midazolam for painful procedures in pediatric oncology patients.
        J Clin Oncol. 1997; 15: 94-102
        • Green SM
        • Hummel CB
        • Wittlake WA
        • et al.
        What is the optimal dose of intramuscular ketamine for pediatric sedation?.
        Acad Emerg Med. 1999; 6: 21-26
        • Petrack EM
        • Marx CM
        • Wright MS.
        Intramuscular ketamine is superior to meperidine, promethazine, and chlorpromazine for pediatric emergency department sedation.
        Arch Pediatr Adolesc Med. 1996; 150: 676-681
        • Kennedy RM
        • McAllister JD.
        Midazolam with ketamine: who benefits?.
        Ann Emerg Med. 2000; 35: 297-299
        • Green SM
        • Rothrock SG
        • Lynch EL
        • et al.
        Intramuscular ketamine for pediatric sedation in the emergency department: safety profile in 1,022 cases.
        Ann Emerg Med. 1998; 31: 688-697
        • Green SM
        • Kuppermann N
        • Rothrock SG
        • et al.
        Predictors of adverse events with intramuscular ketamine sedation in children.
        Ann Emerg Med. 2000; 35: 35-42
        • Splinter WM
        • MacNeill HB
        • Menard EA
        • et al.
        Midazolam reduces vomiting after tonsillectomy in children.
        Can J Anaesth. 1995; 42: 201-203
        • Olynyk JK
        • Cullen SR
        • Leahy MF.
        Midazolam: an effective antiemetic agent for cytotoxic chemotherapy [letter].
        Med J Aust. 1989; 150: 466
        • Robins HI
        • Ershler WB
        • De Jongh L.
        Antiemetic effect of intravenous diazepam in patients receiving cis-diamminedichloroplatinum II: a pilot study.
        Med Pediatr Oncol. 1979; 7: 247-249
        • Kearsley JH
        • Williams AM
        • Fiumara AM.
        Antiemetic superiority of lorazepam over oxazepam and methlyprednisolone as premedicants for patients receiving cisplatin-containing chemotherapy.
        Cancer. 1989; 64: 1595-1599
        • Khalil SN
        • Berry JM
        • Howard G
        • et al.
        Antiemetic effect of lorazepam after outpatient strabismus surgery in children.
        Anesthesiology. 1992; 77: 915-919
        • Perel A
        • Davidson JT.
        Recurrent hallucinations following ketamine.
        Anaesthesia. 1976; 31: 1081-1083
        • Meyers EF
        • Charles P.
        Prolonged adverse reactions to ketamine in children.
        Anesthesiology. 1978; 49: 39-40